PrenatalSAFE 5 NIPT Blood Test

Descripción Del Producto

PrenatalSAFE® 5 occupies a key tier within the clinical PrenatalSAFE® family (which spans PrenatalSAFE 3, PrenatalSAFE Plus, Karyo, and Complete). While traditional national healthcare screening pathways (such as the NHS combined test) rely on maternal serum biochemical markers (PAPP-A, free $\beta$-hCG) paired with ultrasound nuchal translucency (NT) measurement—yielding detection rates around 85% with a 5% false-positive rate—PrenatalSAFE 5 utilizes massive parallel sequencing of placental DNA fragments in maternal circulation to achieve detection rates of up to 99.5% with false-positive rates below 0.1%.

Diagnostic Scope & Chromosomal Targets

• Primary Autosomal Aneuploidies:

  • Trisomy 21 (Down Syndrome): Most common viable autosomal aneuploidy ($1\text{ in }700\text{ live births}$), characterized by variable intellectual disability, congenital heart defects, and characteristic physical features.

  • Trisomy 18 (Edwards Syndrome): Severe chromosomal condition ($1\text{ in }3,000\text{ to }5,000\text{ births}$) involving microcephaly, congenital cardiac and renal malformations, and high intrauterine lethality.

  • Trisomy 13 (Patau Syndrome): Severe aneuploidy ($1\text{ in }6,000\text{ to }10,000\text{ births}$) characterized by holoprosencephaly, midline facial clefts, and polydactyly.

• Sex Chromosome Aneuploidies (SCAs):

  • Monosomy X / $45,X$ (Turner Syndrome): Complete or partial absence of one X chromosome in females, presenting with short stature, ovarian dysgenesis, and aortic coarctation.

  • $47,XXY$ (Klinefelter Syndrome): Presence of an extra X chromosome in males, leading to testicular dysgenesis, hypergonadotropic hypogonadism, tall stature, and gynecomastia.

  • $47,XYY$ (Jacobs Syndrome): Male phenotype featuring an additional Y chromosome, commonly associated with tall stature and variable neurodevelopmental delays.

  • $47,XXX$ (Triple X Syndrome): Female phenotype characterized by an additional X chromosome, associated with tall stature and language/learning differences.

• Fetal Biological Sex Determination: Optional analysis of Y-chromosome genetic markers to establish fetal biological sex in singleton and monozygotic twin gestations with $>99.9\%$ accuracy.

Molecular Genetics & Next-Generation Sequencing (NGS) Mechanics

1. Biological Origin of $cffDNA$: During pregnancy, syncytiotrophoblast cells of the placenta undergo continuous apoptosis, shedding short, fragmented extracellular DNA pieces (140 to 160 base pairs) into the maternal vascular bed.

2. Venipuncture & Plasma Fractionation: Maternal peripheral whole blood ($8\text{–}10\text{ mL}$) is drawn into dedicated blood collection tubes containing cell-stabilizing reagents (e.g., Streck Cell-Free DNA BCT®). The preservative prevents maternal nucleated white blood cells from lysing and diluting the fetal fraction. Centrifugation separates cell-free plasma from the cellular pelleted fraction.

3. Automated Library Preparation & Barcoding: High-yield automated magnetic bead systems isolate low-molecular-weight cell-free circulating DNA. Molecular adapters and unique sample-specific barcode sequences are ligated to DNA fragment ends to construct high-complexity sequencing libraries.

4. Massively Parallel Shotgun Sequencing (MPSS): Libraries undergo high-throughput Next-Generation Sequencing (Illumina platforms). Millions of sequence tags are generated per flow cell, reading individual $cffDNA$ molecules.

5. Bioinformatic Alignment & $Z$-Score Calculation:

   • Reads are computationally aligned against the reference human genome ($\text{GRCh38/hg38}$).

   • The platform calculates the relative proportional representation of sequence fragments mapping to each specific chromosome.

   • A normalized chromosome value or $Z$-score is computed: if fragments mapping to chromosome 21, 18, 13, X, or Y significantly exceed statistical expectations based on maternal background reference distributions, an aneuploidy is identified.

PrenatalSAFE Kit Packaging. Source: OrizzonteNascita / Prenatalsafe®: il test di screening prenatale non invasivo

*Note: Positive Predictive Value (PPV) reflects the probability that a positive screening result represents an affected fetus and is modulated by maternal age and prior baseline risk.

Pre-Analytical Requirements & Clinical Workflow

• Gestational Age Cut-Off: Validated for performance starting strictly at 10 full weeks of gestation ($10+0\text{ weeks}$, calculated via first-trimester dating ultrasound scan). Sampling prior to week 10 risks non-informative results due to insufficient circulating fetal fraction.

• Fetal Fraction Threshold: The assay requires a minimum fetal fraction (typically $\ge 4\%$). If maternal plasma contains an inadequate fetal fraction, a “no-call” or test failure occurs, requiring a redraw at a later gestational week.

• Turnaround Window: Laboratory processing is typically completed within 3 to 7 business days from specimen arrival at the sequencing facility.

• Pregnancy Modalities Supported: Validated for singleton pregnancies conceived naturally or via assisted reproductive technologies (IVF, ICSI), including autologous or egg-donor/sperm-donor conceptions.

Diagnostic Limitations & Complex Biological Confounders

• Screening vs. Diagnostic Modality: NIPT is a high-accuracy screening tool, not a definitive diagnostic test. A “Low Risk” (negative) result significantly lowers statistical probability but cannot guarantee the absence of all chromosomal defects. A “High Risk” (positive) result mandates confirmatory diagnostic testing via invasive procedures (chorionic villus sampling [CVS] or amniocentesis with karyotyping or chromosomal microarray) before any irreversible medical decisions are made.

• Confined Placental Mosaicism (CPM): Because circulating $cffDNA$ originates from placental syncytiotrophoblasts rather than the fetus proper, chromosomal discordance can occur. In 1% to 2% of pregnancies, genetic mutations or aneuploid cell lines are confined solely to the placenta while the fetus remains euploid, generating a false-positive NIPT result.

• Vanishing Twin Syndrome: In pregnancies that began as multiple gestations where one sac underwent early demised resorption, apoptotic $cffDNA$ from the demised twin can persist in maternal circulation for weeks, yielding false-positive trisomy or discordant sex chromosome readings.

• Multiple Gestations (Twin Restrictions): PrenatalSAFE 5 can evaluate basic trisomies in twin pregnancies; however, sex chromosome aneuploidy (SCA) evaluation is restricted to singleton gestations. In dichorionic twins, the assay can verify the presence or absence of the Y chromosome, but cannot attribute sex chromosome aneuploidies to an individual fetus.

• Maternal Genomic Aberrations: Maternal sex chromosome mosaicism (e.g., undiagnosed low-level maternal $45,X/46,XX$), maternal copy number variations (CNVs), or occult maternal hematologic malignancies can shed discordant cell-free DNA into plasma, resulting in false-positive aneuploidy calls.

Regulatory Framework & Post-Test Clinical Care

• Laboratory Standards & Markings: Processed in ISO 15189, CAP-accredited, and CLIA-certified medical genetics laboratories. Reagent panels and analytical workflows operate under European In Vitro Diagnostic Medical Device certifications (CE-IVD).

• Genetic Counseling Mandate: Clinical protocol requires access to formal pre-test and post-test genetic counseling. Certified genetic counselors interpret complex positive predictive value calculations, discuss biological limitations (such as mosaicism), and guide referrals for diagnostic amniocentesis.